{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T13:07:36Z","timestamp":1783429656704,"version":"3.54.6"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40257-025-00965-5","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:39:37Z","timestamp":1753173577000},"page":"695-710","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Burden of Pediatric Psoriasis: A Systematic Review"],"prefix":"10.1007","volume":"26","author":[{"given":"Angela","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke M. B.","family":"Seyger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Stoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly M.","family":"Cordoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6187-6549","authenticated-orcid":false,"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"3","key":"965_CR1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/j.1365-2133.2009.09593.x","volume":"162","author":"M Augustin","year":"2010","unstructured":"Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Sch\u00e4fer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633\u20136.","journal-title":"Br J Dermatol"},{"issue":"2","key":"965_CR2","first-page":"187","volume":"17","author":"AS Paller","year":"2018","unstructured":"Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Gu\u00e9rin A, et al. Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis. J Drugs Dermatol. 2018;17(2):187\u201394.","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"965_CR3","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1001\/archderm.141.12.1537","volume":"141","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol. 2005;141(12):1537\u201341.","journal-title":"Arch Dermatol"},{"issue":"2","key":"965_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2340\/00015555-0591","volume":"89","author":"L Naldi","year":"2009","unstructured":"Naldi L, Parazzini F, Gallus S. Prevalence of atopic dermatitis in Italian schoolchildren: factors affecting its variation. Acta Derm Venereol. 2009;89(2):122\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"965_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055477","volume":"12","author":"N da Silva","year":"2022","unstructured":"da Silva N, Augustin M, Hilbring C, Braren-von St\u00fclpnagel CC, Sommer R. Psychological (co)morbidity in patients with psoriasis: the impact of pruritus and anogenital involvement on symptoms of depression and anxiety and on body dysmorphic concerns\u2014a cross-sectional study. BMJ Open. 2022;12(9): e055477.","journal-title":"BMJ Open"},{"issue":"5","key":"965_CR6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","volume":"17","author":"IM Bronckers","year":"2015","unstructured":"Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in children and adolescents: diagnosis, management and comorbidities. Paediatr Drugs. 2015;17(5):373\u201384.","journal-title":"Paediatr Drugs"},{"key":"965_CR7","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.2340\/actadv.v103.2544","volume":"103","author":"MMB Seyger","year":"2023","unstructured":"Seyger MMB, Paller AS, Sticherling M, Bachhuber T, Thomas N, Hetherington J, et al. Patient-reported outcomes and burden of disease in paediatric patients with psoriasis: real-world data from EU5 and US. Acta Dermato-Venereol. 2023;103:2544.","journal-title":"Acta Dermato-Venereol"},{"issue":"1","key":"965_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.acap.2014.08.004","volume":"15","author":"J Quach","year":"2015","unstructured":"Quach J, Barnett T. Impact of chronic illness timing and persistence at school entry on child and parent outcomes: Australian longitudinal study. Acad Pediatr. 2015;15(1):89\u201395.","journal-title":"Acad Pediatr"},{"issue":"207\u201312","key":"965_CR9","volume":"246","author":"CB Forrest","year":"2022","unstructured":"Forrest CB, Schuchard J, Bruno C, Amaral S, Cox ED, Flynn KE, et al. Self-reported health outcomes of children and youth with 10 chronic diseases. J Pediatr. 2022;246(207\u201312): e1.","journal-title":"J Pediatr"},{"issue":"7","key":"965_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/jcpp.12727","volume":"58","author":"E Secinti","year":"2017","unstructured":"Secinti E, Thompson EJ, Richards M, Gaysina D. Research review: childhood chronic physical illness and adult emotional health\u2014a systematic review and meta-analysis. J Child Psychol Psychiatry. 2017;58(7):753\u201369.","journal-title":"J Child Psychol Psychiatry"},{"issue":"2","key":"965_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.19147","volume":"183","author":"A Paller","year":"2020","unstructured":"Paller A, Seyger M, Alejandro Magarinos G, Bagel J, Pinter A, Cather J, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231\u201341.","journal-title":"Br J Dermatol"},{"issue":"2","key":"965_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/pde.14403","volume":"38","author":"S Mannix","year":"2021","unstructured":"Mannix S, Edson-Heredia E, Paller A, Yosipovitch G, Burge R, Kleinman L. The experience of itch in children with psoriasis: a qualitative exploration of the Itch Numeric Rating Scale. Pediatr Dermatol. 2021;38(2):405\u201312.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"965_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2133.2006.07185.x","volume":"155","author":"PE Beattie","year":"2006","unstructured":"Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol. 2006;155(1):145\u201351.","journal-title":"Br J Dermatol"},{"issue":"6","key":"965_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamadermatol.2024.0594","volume":"160","author":"AS Paller","year":"2024","unstructured":"Paller AS, Rangel SM, Chamlin SL, Hajek A, Phan S, Hogeling M, et al. Stigmatization and mental health impact of chronic pediatric skin disorders. JAMA Dermatol. 2024;160(6):621\u201330.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"965_CR15","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/j.1365-2133.2010.09993.x","volume":"163","author":"M de Jager","year":"2010","unstructured":"de Jager M, van de Kerkhof P, de Jong E, Seyger M. A cross-sectional study using the children\u2019s dermatology life quality index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. Br J Dermatol. 2010;163(5):1099\u2013101.","journal-title":"Br J Dermatol"},{"issue":"15","key":"965_CR16","doi-asserted-by":"publisher","first-page":"adv00244","DOI":"10.2340\/00015555-3602","volume":"100","author":"M Zychowska","year":"2020","unstructured":"Zychowska M, Reich A, Maj J, Jankowska-Konsur A, Szepietowski J. Impact of childhood psoriasis on caregivers\u2019 quality of life, measured with family dermatology life quality index. Acta Derm Venereol. 2020;100(15):adv00244.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"965_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/pde.13772","volume":"36","author":"AS Paller","year":"2019","unstructured":"Paller AS, Schenfeld J, Accortt NA, Kricorian G. A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population. Pediatr Dermatol. 2019;36(3):290\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"965_CR18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jaad.2011.11.948","volume":"67","author":"A Kimball","year":"2012","unstructured":"Kimball A, Wu E, Guerin A, Yu A, Tsaneva M, Gupta S, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651-7.e1-2.","journal-title":"J Am Acad Dermatol"},{"key":"965_CR19","unstructured":"Chang SM, Matchar DB, Smetana GW, Umscheid CA. Methods Guide for Medical Test Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012."},{"issue":"11","key":"965_CR20","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jclinepi.2012.06.001","volume":"65","author":"JR Treadwell","year":"2012","unstructured":"Treadwell JR, Singh S, Talati R, McPheeters ML, Reston JT. A framework for best evidence approaches can improve the transparency of systematic reviews. J Clin Epidemiol. 2012;65(11):1159\u201362.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"965_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0895-4356(94)00097-A","volume":"48","author":"RE Slavin","year":"1995","unstructured":"Slavin RE. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol. 1995;48(1):9\u201318.","journal-title":"J Clin Epidemiol"},{"key":"965_CR22","unstructured":"Oxford Centre for Evidence-Based Medicine: Levels of Evidence. 2009 [cited 2025 26 April]. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009"},{"issue":"5","key":"965_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/pde.13585","volume":"35","author":"B Tekin","year":"2018","unstructured":"Tekin B, Gurel M, Topkarci Z, Topaloglu Demir F, Aytekin S, Cebeci Kahraman F, et al. Assessment of quality of life in Turkish children with psoriasis and their caregivers. Pediatr Dermatol. 2018;35(5):651\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"965_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/pde.14891","volume":"39","author":"P Nourmohammadpour","year":"2022","unstructured":"Nourmohammadpour P, Ehsani AH, Hatami P, Fakoor Y, Fahim S, Mohsenolhosseini Z, et al. Do clinical severity scores correlate with the quality of life in children with psoriasis? A cross-sectional study of Iranian pediatric patients. Pediatr Dermatol. 2022;39(2):211\u20134.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"965_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2133.2012.10996.x","volume":"167","author":"A Oostveen","year":"2012","unstructured":"Oostveen A, de Jager M, van de Kerkhof P, Donders A, de Jong E, Seyger M. The influence of treatments in daily clinical practice on the children\u2019s dermatology life quality index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Br J Dermatol. 2012;167(1):145\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"965_CR26","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1525-1470.2010.01292.x","volume":"28","author":"A Ganemo","year":"2011","unstructured":"Ganemo A, Wahlgren C, Svensson A. Quality of life and clinical features in Swedish children with psoriasis. Pediatr Dermatol. 2011;28(4):375\u20139.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"965_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1684\/ejd.2021.4127","volume":"31","author":"F Bardazzi","year":"2021","unstructured":"Bardazzi F, Chessa M, Patrizi A, Iommi M, Rucci P, Ali F, et al. The impact of psoriasis on quality of life of children and their caregivers: an Italian experience. Eur J Dermatol. 2021;31(5):649\u201350.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"965_CR28","first-page":"374","volume":"156","author":"F Caroppo","year":"2021","unstructured":"Caroppo F, Zacchino M, Milazzo E, Fontana E, Nobile F, Marogna C, et al. Quality of life in children with psoriasis: results from a monocentric study. Ital J Dermatol Venerol. 2021;156(3):374\u20137.","journal-title":"Ital J Dermatol Venerol."},{"issue":"2","key":"965_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2340\/00015555-1622","volume":"94","author":"A Oostveen","year":"2014","unstructured":"Oostveen A, Jong E, Evers A, Donders A, van de Kerkhof P, Seyger M. Reliability, responsiveness and validity of Scalpdex in children with scalp psoriasis: the Dutch study. Acta Derm Venereol. 2014;94(2):198\u2013202.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"965_CR30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000503062","volume":"236","author":"N AlMutairi","year":"2020","unstructured":"AlMutairi N, Nour T. Tofacitinib in pediatric psoriasis: an open-label trial to study its safety and efficacy in children. Dermatology. 2020;236(3):191\u20138.","journal-title":"Dermatology"},{"issue":"4","key":"965_CR31","first-page":"469","volume":"153","author":"V Arese","year":"2018","unstructured":"Arese V, Albini P, Ibba F, Panzone M, Cervetti O. Juvenile psoriasis: an epidemiological study of 69 cases. G Ital Dermatol Venereol. 2018;153(4):469\u201372.","journal-title":"G Ital Dermatol Venereol"},{"issue":"1","key":"965_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/bjd.19747","volume":"185","author":"H Hamm","year":"2021","unstructured":"Hamm H, Wilsmann-Theis D, Tsianakas A, Gambichler T, Taipale K, Lauterbach J, et al. Efficacy and safety of fumaric acid esters in young patients aged 10\u201317 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial. Br J Dermatol. 2021;185(1):62\u201373.","journal-title":"Br J Dermatol"},{"issue":"4","key":"965_CR33","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","volume":"73","author":"I Landells","year":"2015","unstructured":"Landells I, Marano C, Hsu M, Li S, Zhu Y, Eichenfield L, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594\u2013603.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"965_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jaad.2010.02.060","volume":"64","author":"R Langley","year":"2011","unstructured":"Langley R, Paller A, Hebert A, Creamer K, Weng H, Jahreis A, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol. 2011;64(1):64\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"965_CR35","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/jdv.12789","volume":"29","author":"A Oostveen","year":"2015","unstructured":"Oostveen A, de Jong E, Donders A, van de Kerkhof P, Seyger M. Treatment of paediatric scalp psoriasis with calcipotriene\/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children\u2019s quality of life in daily practice. J Eur Acad Dermatol Venereol. 2015;29(6):1193\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"965_CR36","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.19018","volume":"183","author":"S Philipp","year":"2020","unstructured":"Philipp S, Menter A, Nikkels A, Barber K, Landells I, Eichenfield L, et al. Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (>= 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study. Br J Dermatol. 2020;183(4):664\u201372.","journal-title":"Br J Dermatol"},{"issue":"5","key":"965_CR37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3109\/09546634.2014.996515","volume":"26","author":"M van Geel","year":"2015","unstructured":"van Geel M, Oostveen A, Hoppenreijs E, Hendriks J, van de Kerkhof P, de Jong E, et al. Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry. J Dermatol Treat. 2015;26(5):406\u201312.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"965_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/bjd.15120","volume":"176","author":"M van Geel","year":"2017","unstructured":"van Geel M, Otero M, de Jong E, van de Kerkhof P, Seyger M. Validation of the simplified psoriasis index in Dutch children and adolescents with plaque psoriasis. Br J Dermatol. 2017;176(3):771\u20136.","journal-title":"Br J Dermatol"},{"issue":"3","key":"965_CR39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/jdv.16930","volume":"35","author":"M Zychowska","year":"2021","unstructured":"Zychowska M, Reich A, Maj J, Jankowska-Konsur A, Szepietowski J. Comparison of the impact of childhood psoriasis on mothers\u2019 and fathers\u2019 quality of life\u2014does gender of a caregiver play a role? J Eur Acad Dermatol Venereol. 2021;35(3):685\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"965_CR40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1111\/j.1365-2133.2010.10196.x","volume":"164","author":"L Chiam","year":"2011","unstructured":"Chiam L, de Jager M, Giam Y, de Jong E, van de Kerkhof P, Seyger M. Juvenile psoriasis in European and Asian children: similarities and differences. Br J Dermatol. 2011;164(5):1101\u20133.","journal-title":"Br J Dermatol"},{"issue":"4","key":"965_CR41","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1111\/ajd.12491","volume":"58","author":"T Ergun","year":"2017","unstructured":"Ergun T, Seckin Gencosmanoglu D, Karakoc-Aydiner E, Salman A, Tekin B, Bulbul-Baskan E, et al. Prevalence of obesity in paediatric psoriasis and its impact on disease severity and progression. Australas J Dermatol. 2017;58(4):e182\u20137.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"965_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ced.14373","volume":"46","author":"E Forward","year":"2021","unstructured":"Forward E, Lee G, Fischer G. Shades of grey: what is paediatric psoriasiform dermatitis and what does it have in common with childhood psoriasis? Clin Exp Dermatol. 2021;46(1):65\u201373.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"965_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/LGT.0b013e31824b9e5e","volume":"16","author":"S Kapila","year":"2012","unstructured":"Kapila S, Bradford J, Fischer G. Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature. J Low Genit Tract Dis. 2012;16(4):364\u201371.","journal-title":"J Low Genit Tract Dis"},{"issue":"2","key":"965_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1440-0960.2012.00878.x","volume":"53","author":"S Kapila","year":"2012","unstructured":"Kapila S, Hong E, Fischer G. A comparative study of childhood psoriasis and atopic dermatitis and greater understanding of the overlapping condition, psoriasis-dermatitis. Australas J Dermatol. 2012;53(2):98\u2013105.","journal-title":"Australas J Dermatol"},{"issue":"2","key":"965_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1046\/j.1365-2230.2000.00598.x","volume":"25","author":"A Nanda","year":"2000","unstructured":"Nanda A, Al-Fouzan A, El-Kashlan M, Al-Sweih N, Al-Muzairai I. Salient features and HLA markers of childhood psoriasis in Kuwait. Clin Exp Dermatol. 2000;25(2):147\u201351.","journal-title":"Clin Exp Dermatol"},{"key":"965_CR46","doi-asserted-by":"publisher","first-page":"adv00660","DOI":"10.2340\/actadv.v101.981","volume":"102","author":"MMB Seyger","year":"2022","unstructured":"Seyger MMB, Augustin M, Sticherling M, Bachhuber T, Fang J, Hetherington J, et al. Physician-reported clinical unmet needs, burden and treatment patterns of paediatric psoriasis patients: a US and EU real-world evidence study. Acta Derm Venereol. 2022;102:adv00660.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"965_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12519-010-0213-0","volume":"6","author":"Y Wu","year":"2010","unstructured":"Wu Y, Lin Y, Liu H, Huang C, Feng A, Li J. Childhood psoriasis: a study of 137 cases from central China. World J Pediatr. 2010;6(3):260\u20134.","journal-title":"World J Pediatr"},{"issue":"3 Suppl","key":"965_CR48","first-page":"87","volume":"26","author":"G Damiani","year":"2022","unstructured":"Damiani G, Finelli R, Kridin K, Pacifico A, Bragazzi NL, Malagoli P, et al. Chilblain-like lesions (COVID-19 toes) have the same impact on family members than psoriasis systemically treated: insights from a case-control study targeting the pediatric population. Eur Rev Med Pharmacol Sci. 2022;26(3 Suppl):87\u201393.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"965_CR49","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/pde.14388","volume":"37","author":"M Zychowska","year":"2020","unstructured":"Zychowska M. Depressive symptoms among mothers of children with psoriasis\u2014a case-control study. Pediatr Dermatol. 2020;37(6):1038\u201343.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"965_CR50","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jid.2021.10.015","volume":"142","author":"AS Paller","year":"2022","unstructured":"Paller AS, Lai JS, Jackson K, Rangel SM, Nowinski C, Silverberg JI, et al. Generation and validation of the patient-reported outcome measurement information system itch questionnaire-child (PIQ-C) to measure the impact of itch on life quality. J Invest Dermatol. 2022;142(5):1309-1317e1.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"965_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/pde.14892","volume":"39","author":"AA Hebert","year":"2022","unstructured":"Hebert AA, Bobonich MA, Rodriguez Capriles C, Gallo G, Li L, Somani N, et al. Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis. Pediatr Dermatol. 2022;39(1):55\u201360.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"965_CR52","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1159\/000521262","volume":"238","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chen Y, Xiang X, Gu Y, Zhao M, Liu Y, et al. Systemic methotrexate treatment in 42 children with severe plaque psoriasis: a retrospective study in China. Dermatology. 2022;238(5):919\u201327.","journal-title":"Dermatology"},{"issue":"1","key":"965_CR53","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/pde.12429","volume":"32","author":"L Eichenfield","year":"2015","unstructured":"Eichenfield L, Ganslandt C, Kurvits M, Schlessinger J. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years. Pediatr Dermatol. 2015;32(1):28\u201335.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"965_CR54","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1346-8138.2011.01452.x","volume":"39","author":"H Kwon","year":"2012","unstructured":"Kwon H, Na S, Jo S, Youn J. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 2012;39(3):260\u20134.","journal-title":"J Dermatol"},{"issue":"9","key":"965_CR55","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1111\/jdv.16233","volume":"34","author":"M Seyger","year":"2020","unstructured":"Seyger M, Abramovits W, Liljedahl M, Hoejen M, Teng J. Safety and efficacy of fixed-dose combination calcipotriol (50 mug\/g) and betamethasone dipropionate (0.5 mg\/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial. J Eur Acad Dermatol Venereol. 2020;34(9):2026\u201334.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"965_CR56","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/jamadermatol.2019.3717","volume":"156","author":"F Bruins","year":"2020","unstructured":"Bruins F, Bronckers I, Groenewoud H, van de Kerkhof P, de Jong E, Seyger M. Association between quality of life and improvement in psoriasis severity and extent in pediatric patients. JAMA Dermatol. 2020;156(1):72\u20138.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"965_CR57","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1590\/S0365-05962012000300002","volume":"87","author":"A Manzoni","year":"2012","unstructured":"Manzoni A, Pereira R, Townsend R, Weber M, Nagatomi A, Cestari T. Assessment of the quality of life of pediatric patients with the major chronic childhood skin diseases. An Bras Dermatol. 2012;87(3):361\u20138.","journal-title":"An Bras Dermatol"},{"issue":"6","key":"965_CR58","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1590\/abd1806-4841.20131915","volume":"88","author":"AP Manzoni","year":"2013","unstructured":"Manzoni AP, Weber MB, Nagatomi AR, Pereira RL, Townsend RZ, Cestari TF. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol. 2013;88(6):894\u20139.","journal-title":"An Bras Dermatol"},{"issue":"6","key":"965_CR59","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1590\/abd1806-4841.20186981","volume":"93","author":"A Salman","year":"2018","unstructured":"Salman A, Yucelten A, Sarac E, Saricam M, Perdahli-Fis N. Impact of psoriasis in the quality of life of children, adolescents and their families: a cross-sectional study. An Bras Dermatol. 2018;93(6):819\u201323.","journal-title":"An Bras Dermatol"},{"issue":"4","key":"965_CR60","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1684\/ejd.2016.2785","volume":"26","author":"M Van Geel","year":"2016","unstructured":"Van Geel M, Spillekom-Van Koulil S, Oostveen A, Van De Kerkhof P, Klompmaker-Van Den Hoek W, Teunissen M, et al. An outpatient multidisciplinary training programme for children and adolescents with psoriasis and their parents: a pilot study. Eur J Dermatol. 2016;26(4):393\u20135.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"965_CR61","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/pde.15297","volume":"40","author":"A Horev","year":"2023","unstructured":"Horev A, Grinshpun K, Forer E, Weissmann S, Bari R, Sagie N, et al. Pediatric psoriasis negatively influences parental sleep quality. Pediatr Dermatol. 2023;40(4):610\u20134.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"965_CR62","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjd.12895","volume":"171","author":"M van Geel","year":"2014","unstructured":"van Geel M, Mul K, Oostveen A, van de Kerkhof P, de Jong E, Seyger M. Calcipotriol\/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort. Br J Dermatol. 2014;171(2):363\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"965_CR63","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000381913","volume":"231","author":"M Augustin","year":"2015","unstructured":"Augustin M, Radtke M, Glaeske G, Reich K, Christophers E, Schaefer I, et al. Epidemiology and comorbidity in children with psoriasis and atopic eczema. Dermatology. 2015;231(1):35\u201340.","journal-title":"Dermatology"},{"issue":"1","key":"965_CR64","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/pde.12205","volume":"31","author":"D Matusiewicz","year":"2014","unstructured":"Matusiewicz D, Koerber A, Schadendorf D, Wasem J, Neumann A. Childhood psoriasis\u2014an analysis of German health insurance data. Pediatr Dermatol. 2014;31(1):8\u201313.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"965_CR65","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000499564","volume":"235","author":"K Patel","year":"2019","unstructured":"Patel K, Lee H, Rastogi S, Singam V, Vakharia P, Silverberg J. Association of psoriasis with psychiatric hospitalization in United States children and adults. Dermatology. 2019;235(4):276\u201386.","journal-title":"Dermatology"},{"issue":"4","key":"965_CR66","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/bjd.16031","volume":"178","author":"E Galili","year":"2018","unstructured":"Galili E, Barzilai A, Shreberk-Hassidim R, Merdler I, Caspi T, Astman N. Neuropsychiatric comorbidity among adolescents with psoriasis. Br J Dermatol. 2018;178(4):910\u20136.","journal-title":"Br J Dermatol"},{"issue":"6","key":"965_CR67","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1442-200X.2006.02270.x","volume":"48","author":"M Seyhan","year":"2006","unstructured":"Seyhan M, Coskun B, Saglam H, Ozcan H, Karincaoglu Y. Psoriasis in childhood and adolescence: evaluation of demographic and clinical features. Pediatr Int. 2006;48(6):525\u201330.","journal-title":"Pediatr Int"},{"issue":"6","key":"965_CR68","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1525-1470.2010.01195.x","volume":"27","author":"A Bilgic","year":"2010","unstructured":"Bilgic A, Bilgic O, Akis H, Eskioglu F, Kilic E. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Dermatol. 2010;27(6):614\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"7","key":"965_CR69","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1111\/jdv.16229","volume":"34","author":"C Blegvad","year":"2020","unstructured":"Blegvad C, Nybo Andersen A, Groot J, Zachariae C, Barker J, Skov L. Clinical characteristics including cardiovascular and metabolic risk factors in adolescents with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(7):1516\u201323.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"965_CR70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5021\/ad.2020.32.3.181","volume":"32","author":"E Alpsoy","year":"2020","unstructured":"Alpsoy E, Polat M, Yavuz IH, Kartal P, Didar Balci D, Karadag AS, et al. Internalized stigma in pediatric psoriasis: a comparative multicenter study. Ann Dermatol. 2020;32(3):181\u20138.","journal-title":"Ann Dermatol"},{"issue":"6","key":"965_CR71","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","volume":"132","author":"MS Lewis-Jones","year":"1995","unstructured":"Lewis-Jones MS, Finlay AY. The children\u2019s dermatology life quality index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942\u20139.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"965_CR72","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00787-008-1014-z","volume":"17","author":"M Bullinger","year":"2008","unstructured":"Bullinger M, Br\u00fctt AL, Erhart M, Ravens-Sieberer U. Psychometric properties of the KINDL-R questionnaire: results of the BELLA study. Eur Child Adolesc Psychiatry. 2008;17(Suppl 1):125\u201332.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"8","key":"965_CR73","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the pediatric quality of life inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39(8):800\u201312.","journal-title":"Med Care"},{"issue":"4","key":"965_CR74","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jaad.2021.02.069","volume":"85","author":"B Cheng","year":"2021","unstructured":"Cheng B, Silverberg J. Association of pediatric atopic dermatitis and psoriasis with school absenteeism and parental work absenteeism: a cross-sectional United States population-based study. J Am Acad Dermatol. 2021;85(4):885\u201392.","journal-title":"J Am Acad Dermatol"},{"key":"965_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jpsychores.2016.03.010","volume":"84","author":"U Matterne","year":"2016","unstructured":"Matterne U, Apfelbacher C. Peer-relationship-problems account for quality of life impairments in pediatric psoriasis. J Psychosom Res. 2016;84:31\u20136.","journal-title":"J Psychosom Res"},{"issue":"1","key":"965_CR76","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/bjd.14163","volume":"174","author":"M van Geel","year":"2016","unstructured":"van Geel M, Maatkamp M, Oostveen A, de Jong E, Finlay A, van de Kerkhof P, et al. Comparison of the dermatology life quality index and the children\u2019s dermatology life quality index in assessment of quality of life in patients with psoriasis aged 16\u201317 years. Br J Dermatol. 2016;174(1):152\u20137.","journal-title":"Br J Dermatol"},{"issue":"3","key":"965_CR77","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/bjd.19301","volume":"184","author":"F Bruins","year":"2021","unstructured":"Bruins F, Bronckers I, Cai R, Groenewoud J, Krol M, de Jong E, et al. Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective, longitudinal, observational cohort study of 448 patients. Br J Dermatol. 2021;184(3):464\u201372.","journal-title":"Br J Dermatol"},{"issue":"3","key":"965_CR78","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00431-011-1587-2","volume":"171","author":"J Varni","year":"2012","unstructured":"Varni J, Globe D, Gandra S, Harrison D, Hooper M, Baumgartner S. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485\u201392.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"965_CR79","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s42358-020-00136-6","volume":"60","author":"T Meneghetti","year":"2020","unstructured":"Meneghetti T, Padilha T, Azevedo V, Cat M, Sarolli B, de Carvalho V. The musculoskeletal impairment negatively impacts the quality of life of children and adolescents with psoriasis. Adv Rheumatol. 2020;60(1):33.","journal-title":"Adv Rheumatol."},{"issue":"2","key":"965_CR80","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1744-6570.1982.tb02200.x","volume":"35","author":"JH Tubiana","year":"1982","unstructured":"Tubiana JH, Benshakhar G. An objective group questionnaire as a substitute for a personal interview in the prediction of success in military training in Israel. Pers Psychol. 1982;35(2):349\u201357.","journal-title":"Pers Psychol"},{"key":"965_CR81","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s12671-021-01733-2","volume":"12","author":"C Heapy","year":"2021","unstructured":"Heapy C, Norman P, Emerson L, Murphy R, Bogels S, Thompson A. Is parental mindfulness associated with quality of life and itch intensity in children with psoriasis and eczema and well-being in parents? Mindfulness. 2021;12:2707\u201317.","journal-title":"Mindfulness"},{"issue":"9","key":"965_CR82","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1111\/jocd.15737","volume":"22","author":"EAE Elgamal","year":"2023","unstructured":"Elgamal EAE, Aboelwafa HO, Ibrahim AAM, Elshafey MEM. Quality of life in mothers of children with psoriasis. J Cosmet Dermatol. 2023;22(9):2560\u20134.","journal-title":"J Cosmet Dermatol"},{"issue":"2","key":"965_CR83","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ajd.13536","volume":"62","author":"E Kim","year":"2021","unstructured":"Kim E, Fischer G. Relationship between PASI and FDLQI in paediatric psoriasis, and treatments used in daily clinical practice. Australas J Dermatol. 2021;62(2):190\u20134.","journal-title":"Australas J Dermatol"},{"issue":"10","key":"965_CR84","doi-asserted-by":"publisher","first-page":"e855","DOI":"10.1111\/jdv.19942","volume":"38","author":"SE Thomas","year":"2024","unstructured":"Thomas SE, van Reek J, Bruins FM, Groenewoud HMM, de Jong E, Seyger MMB. Unveiling the impact of itch, pain, fatigue and disease severity in paediatric patients with psoriasis and the influence of methotrexate and biologics. J Eur Acad Dermatol Venereol. 2024;38(10):e855\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"965_CR85","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65.e19.","journal-title":"J Am Acad Dermatol"},{"key":"965_CR86","unstructured":"Obtain & Administer Measures. [cited 2025 26 April]; https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis\/obtain-administer-measures"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00965-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T20:03:10Z","timestamp":1757966590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00965-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00965-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"24 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised due to correction in article title.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"International Psoriasis Council.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MMBS received grant from the IPC on definitions for severity of pediatric psoriasis; payments were made to the institution. She served as a consultant for Janssen, BMS, and Novartis; fees were paid directly to the institution. She participated on a DSMB or Advisory Board for Janssen, Eli Lilly, and BMS; payments were made to the institution. She is a Councilor of the IPC. RM is a Councilor of the IPC but has no other conflicts. MLS received payment for events sponsored by the Spondyloarthritis Research and Treatment Network (SPARTAN) and is Chair of SPARTAN. KC is a Councilor of the IPC but has no other conflicts. PvdK received fees for consultancy service or lectureships from Almirall, Eli Lilly, Janssen Pharmaceutica, UCB, and Boehringer Ingelheim. PvdK received honoraria for participating on a DSMB or Advisory Board for BMS and Celtrion. PvdK is Chief Medical Officer of the International Psoriasis Council. AP has been an investigator for AbbVie, Dermavant, Eli Lilly, Johnson & Johnson Innovative Medicine, UCB; a consultant for AbbVie, Arcutis, Boehringer-Ingelheim, Dermavant, LEO, UCB; and participated on a DSMB for AbbVie. AP is on the Board of Directors of the International Psoriasis Council. AP (Amy Paller) is an Editorial Board member of The American Journal of Clinical Dermatology. Professor Paller was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. AY and BC have no conflicts of interest to declare but received monetary support from the IPC for their role in curating data for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Ethics Statement"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This review is unregistered.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registration"}},{"value":"Contact Dr Amy Paller for access.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Protocol"}},{"value":"All data are included within the text, figures, and tables, including supplementary materials.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: AP, PvdK. Data curation: AP, AY, BC. Formal analysis: All authors. Funding acquisition: AP, PvdK. Methodology: All authors. Project administration: AP. Supervision: AP. Writing\u2014original draft: AP, AY, BC. Writing\u2014review and editing: All authors.","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution Statement"}}]}}